) The DNA Sequencing and Analysis Core is now in its 4th year of highly successful operation. Initiated as a fledging operation after the inception of the CU Cancer Center, the Core has grown remarkably with now 112 user groups, of which most are Cancer Center members. In addition to performing DNA sequencing reactions, Core services include preparation of various DNA templates and assisting customers with all technical aspects of DNA sequencing and analysis. The Core also prepares high-density filter arrays using customer prepared libraries. In addition to service functions, Core personnel reported improvements in basic DNA sequencing chemistry that permit longer, more accurate read-lengths and improved mutation detection. To facilitate research efforts of the CU Hereditary Cancer Clinic, the Core now offers screening for the BRCA1/2 185delAG, 5382insC and 6174delT mutations. Especially as a consequence of the Genome Project, the demand for DNA sequencing will continue to expand significantly. During the next period of support, the Core intends to continue its state-of-the-art services to Cancer Center members. Research-based mutation/polymorphism screening is also likely to expand. Over the past 4 years samples sequenced have increased from 1501 to 9410 (526%) and charge back fees have increased from $43,095 to $187,136 (334%). Because of the large increase we have been able to reduce fees which has led to continued increases in core usage. The core has been used by members of 9 of the 10 Cancer Center programs. The core will move to the Fitzsimons campus with the Cancer Center during the next grant cycle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-14
Application #
6478754
Study Section
Project Start
1988-03-01
Project End
2006-01-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
14
Fiscal Year
2001
Total Cost
$144,004
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Shearn, Colin T; Pulliam, Casey F; Pedersen, Kim et al. (2018) Knockout of the Gsta4 Gene in Male Mice Leads to an Altered Pattern of Hepatic Protein Carbonylation and Enhanced Inflammation Following Chronic Consumption of an Ethanol Diet. Alcohol Clin Exp Res 42:1192-1205
Giles, Erin D; Jindal, Sonali; Wellberg, Elizabeth A et al. (2018) Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Res 20:50
Nemkov, Travis; Sun, Kaiqi; Reisz, Julie A et al. (2018) Hypoxia modulates the purine salvage pathway and decreases red blood cell and supernatant levels of hypoxanthine during refrigerated storage. Haematologica 103:361-372
Soontararak, Sirikul; Chow, Lyndah; Johnson, Valerie et al. (2018) Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse Inflammatory Bowel Disease Model. Stem Cells Transl Med 7:456-467
Pennock, Nathan D; Martinson, Holly A; Guo, Qiuchen et al. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer 6:98
Ross, Brian C; Boguslav, Mayla; Weeks, Holly et al. (2018) Simulating heterogeneous populations using Boolean models. BMC Syst Biol 12:64
Wang, Guankui; Benasutti, Halli; Jones, Jessica F et al. (2018) Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles. Colloids Surf B Biointerfaces 161:200-209
Suda, Kenichi; Kim, Jihye; Murakami, Isao et al. (2018) Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 13:1496-1507
Vartuli, Rebecca L; Zhou, Hengbo; Zhang, Lingdi et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 128:2535-2550
Scott, Aaron J; Arcaroli, John J; Bagby, Stacey M et al. (2018) Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Mol Cancer Ther 17:2112-2122

Showing the most recent 10 out of 1634 publications